Medimaps develops advanced deep-tech and AI imaging software to comprehensively assess bone microarchitecture and predict fracture risk in osteoporosis. The company focuses on DXA-based bone densitometry and opportunistic screening, offering solutions like TBS Reveal and TBS Osteo that integrate into clinical workflows and support clinicians in identifying patients at higher fracture risk. Headquartered in Plan-les-Ouates, Switzerland, with a global reach including the United States, Medimaps provides both software tools and professional services for bone health assessment and related pharmaceutical collaborations.
No recent news for this company.